Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib for reduction of bone marrow fibrosis in myelofibrosis with thrombocytopenia
2025-522509-39-00Phase 2Authorised
- Sponsor
- GEMFIN
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pacritinib in myelofibrosis (MF), sponsored by GEMFIN. Primary endpoint: Decrease in reticulin fibrosis grade at week 52. Planned start Mar 2026; status: authorised.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2025-522509-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522509-39-00.